Weeks after closing Bristol Myers deal, Karuna’s ex-CEO heads to Blackstone-backed Anthosnews2024-04-22T19:48:16+00:00April 22nd, 2024|Endpoints News|
Regeneron’s $500M fund spotlights corporate venture’s influential role in biotechnews2024-04-22T19:45:52+00:00April 22nd, 2024|Endpoints News|
Marketing payments to cancer doctors lead to more prescriptions but not better outcomes, NBER paper findsnews2024-04-22T19:36:58+00:00April 22nd, 2024|Endpoints News|
Gene editing startup Seamless hires ex-Homology leader, doubles seed roundnews2024-04-22T19:00:54+00:00April 22nd, 2024|Endpoints News|
Cardinal Health sees its PBM OptumRx contract expire as McKesson takes overnews2024-04-22T17:40:12+00:00April 22nd, 2024|Endpoints News|
Researchers seek FDA transparency on use of surrogate endpoints outside of oncologynews2024-04-22T16:26:35+00:00April 22nd, 2024|Endpoints News|
Biosplice searches for a path forward after osteoarthritis drug fails late-stage studynews2024-04-22T15:33:00+00:00April 22nd, 2024|Endpoints News|
Ipsen, Skyhawk ink deal worth up to $1.8B; Hepion to wind down NASH trialnews2024-04-22T14:41:28+00:00April 22nd, 2024|Endpoints News|
Pfizer to shutter research operations at Colorado site acquired in Array dealnews2024-04-22T14:08:48+00:00April 22nd, 2024|Endpoints News|
Rubedo pulls in $40M Series A to advance atopic dermatitis candidate targeting aging cellsnews2024-04-22T12:36:16+00:00April 22nd, 2024|Endpoints News|
